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Monitoring prevalence of advanced human immunodeficiency 
virus (HIV) disease (i.e., CD4+ T-cell count <200 cells/µL) among 
persons starting antiretroviral therapy (ART) is important to 
understand ART program outcomes, inform HIV preven-
tion strategy, and forecast need for adjunctive therapies.*,†,§ 
To assess trends in prevalence of advanced disease at ART 
initiation in 10 high-burden countries during 2004–2015, 
records of 694,138 ART enrollees aged ≥15 years from 797 
ART facilities were analyzed. Availability of national electronic 
medical record systems allowed up-to-date evaluation of 
trends in Haiti (2004–2015), Mozambique (2004–2014), and 
Namibia (2004–2012), where prevalence of advanced disease 
at ART initiation declined from 75% to 34% (p<0.001), 73% 
to 37% (p<0.001), and 80% to 41% (p<0.001), respectively. 
Significant declines in prevalence of advanced disease during 
2004–2011 were observed in Nigeria, Swaziland, Uganda, 
Vietnam, and Zimbabwe. The encouraging declines in preva-
lence of advanced disease at ART enrollment are likely due to 
scale-up of testing and treatment services and ART-eligibility 
guidelines encouraging earlier ART initiation. However, in 
2015, approximately a third of new ART patients still initi-
ated ART with advanced HIV disease. To reduce prevalence of 
advanced disease at ART initiation, adoption of World Health 
* World Health Organization. Guidelines on co-trimoxazole prophylaxis for 
HIV-related infections among children, adolescents and adults. http://www.
who.int/hiv/pub/guidelines/ctx/en/.
† Wor ld  Hea l th  Organiza t ion .  The  use  o f  l a t e ra l  f low ur ine 
lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of 
active tuberculosis in people living with HIV. http://apps.who.int/iris/
bitstream/10665/193633/1/9789241509633_eng.pdf?ua=1&ua=1.
§ World Health Organization. Rapid advice: diagnosis, prevention and management 
of cryptococcal disease in HIV-infected adults, adolescents and children. http://
apps.who.int/iris/bitstream/10665/44786/1/9789241502979_eng.pdf.
Organization (WHO)–recommended “treat-all” guidelines and 
strategies to facilitate earlier HIV testing and treatment are 
needed to reduce HIV-related mortality and HIV incidence.
Data from 10 countries that requested and received support 
for ART program evaluations through CDC and agreed to 
participate in the analysis were included. Three approaches 
to sampling and analysis were employed (Table 1). In Haiti, 
Mozambique, and Namibia, where large, centralized, electronic 
ART patient monitoring systems are employed, all available 
data from 2004–2015 were analyzed. In each of these countries, 
77%–100% of all ART patients and 67%–100% of all ART 
facilities were captured in the electronic system. In Nigeria, 
Swaziland, Vietnam, and Zimbabwe, nationally representative 
samples of ART facilities were selected, with probability of 
selection proportional to facility size. In Tanzania, Uganda, 
and Zambia, investigators purposively selected health facili-
ties to represent the range of ART facilities in each country 
and ensure that the study remained feasible. Among the seven 
sample-based surveys, a sample frame of study-eligible ART 
patients was created at each selected facility, and simple random 
sampling was used to select the sample of records. Eligibility 
criteria included initiation of ART ≥6 months before data 
abstraction, during 2004–2015, and at age ≥15 years. Data 
were abstracted from ART records onto standardized abstrac-
tion forms by trained study personnel. Because of variations 
in the timing of retrospective data collection for the 10 studies 
(Table 1), the calendar years of ART initiation included in the 
analysis varied among the countries.
The CD4+ T-cell count (CD4) measured in the 6 months 
before ART initiation and closest to the date of ART ini-
tiation was considered the baseline CD4. For each of the 10 
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TABLE 1. Summary of study designs to assess trends in prevalence of advanced disease at antiretroviral therapy enrollment — 10 countries, 
2004–2015
Stage 1: selection of study sites
Region Country
Estimated no. 
ART clinics 
(yr. of assessment)
Estimated no. 
adult ART 
enrollees at 
ART clinics
No. eligible 
clinics*
Estimated no. 
study-eligible adult 
ART enrollees at 
eligible clinics
Site sampling 
technique No. clinics selected
Southern Africa Mozambique 379 (2014) 582,000 254 446,379 Census 254
Namibia 213 (2014) 165,468 213 165,468 Census 213
Swaziland 31 (2009) 50,767 31 50,767 PPS 16
Zimbabwe 104 (2008) 103,806 70 93,811 PPS 40
Zambia 322 (2007) 65,383 129 58,845 Purposive 6
East Africa Tanzania 210 (2007) 41,920 85 37,728 Purposive 6
Uganda 286 (2007) 45,946 114 41,351 Purposive 6
West Africa Nigeria†† 178 (2009) 168,335 139 167,438 PPS 35
Caribbean Haiti 200 (2015) 65,000 191 60,705 Census 191
Southeast Asia Vietnam 173 (2009) 28,090 120 25,000 PPS 30
Total — 2,096 1,316,715 1,346 1,147,492 — 797
Stage 2: selection of study patients
Region Country
Age-eligibility 
criteria (age at ART 
initiation) (yrs)
ART enrollment 
years covered 
by analysis
Patient sampling 
technique at 
selected clinics
Planned 
sample size*
No. eligible 
medical records
analyzed
Date of data 
collection
Southern Africa Mozambique ≥15 2004–2013 Census 446,379 446,379 Dec 2014
Namibia ≥15 2004–2012 Census 165,468 165,468 Dec 2013
Swaziland ≥15 2004–2010 SRS 2,500 2,510 Nov 2011–Feb 2012
Zimbabwe ≥15 2007–2009 SRS 4,000 3,896† Jan–Jun 2010
Zambia ≥18 2004–2009 SRS 1,500 1,214§ Apr–Jul 2010
East Africa Tanzania ≥18 2004–2009 SRS 1,500 1,421¶ Apr–Jul 2010
Uganda ≥18 2004–2009 SRS 1,500 1,466** Apr–Jul 2010
West Africa Nigeria†† ≥15 2004–2011 SRS 3,500 3,496 Dec 2012–Aug 2013
Caribbean Haiti ≥15 2004–2015 Census 60,705 60,705 Jun 2016
Southeast Asia Vietnam ≥15 2005–2009 SRS 7,587 7,583§§ Jan–Jun 2010
Total — — — — 694,639 694,138 —
Abbreviations: ART = antiretroviral therapy; PPS = probability of selection proportional to size; SRS = simple random sampling.
 * To keep sample-based studies feasible, in Zimbabwe, Nigeria, and Vietnam, only facilities with ≥50 adults on ART were eligible for sampling, whereas in Zambia, 
Uganda, and Tanzania, only facilities that had enrolled ≥300 adults on ART were eligible.
 † In Zimbabwe, 23 of 3,919 selected patients with either missing gender (n = 12), or missing outcome (n = 11) were excluded from analysis.
 § In Zambia, among 1,457 records sampled, 243 were excluded because of noncompliance with simple random sampling procedures at one site.
 ¶ In Tanzania, among 1,458 records sampled, one patient was excluded because of absence of age data at ART initiation, and 36 patients enrolled in 2004 were 
excluded because of small sample size for 2004.
 ** In Uganda, among 1,472 records sampled, six patients were excluded because of absence of age data at ART initiation.
 †† In Nigeria, implicit stratification was used in the sampling approach.
 ¶¶ In Vietnam, among 7,587 records sampled, four observations were excluded because information on gender was missing.
countries and for each calendar year, the percentages of adult 
patients with baseline CD4 <100, <200, and <350 cells/µL 
are described with percentages and 95% confidence intervals 
accounting for survey design. Bivariate logistic regression 
models accounting for survey design were used to evaluate 
statistical significance of changes in percentages over calendar 
years, with the likelihood ratio test used to assess departure 
from linear trend over time. Trends in median baseline CD4 
at ART initiation over time are described, and a linear regres-
sion model, accounting for survey design, was used to assess 
statistical significance of changes.
Across the 10 countries, 694,138 adult ART patient records 
were analyzed from 797 ART facilities (Table 1). The overall 
percentage of new ART enrollees during 2004–2015 with 
missing baseline CD4 ranged from 9% in Swaziland to 
53% in Zimbabwe. In the three countries providing more 
recent national electronic medical record data, prevalence 
of advanced disease at ART initiation declined from 73% to 
37% during 2004–2014 in Mozambique, from 80% to 41% 
during 2004–2012 in Namibia, and from 75% to 34% during 
2004–2015 in Haiti (Table 2) (supplemental figure; https://
stacks.cdc.gov/view/cdc/45821). In addition, over the same 
periods, prevalence of CD4 <100/µL declined from 39% to 
18% in Mozambique, from 39% to 16% in Namibia, and 
from 49% to 20% in Haiti. Prevalence of CD4 <350/µL at 
ART initiation also declined over time in all three countries. 
Over the same periods, significant increases in median CD4 
count at ART initiation were observed in Mozambique (from 
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TABLE 2. CD4 distribution among adult antiretroviral therapy enrollees, by calendar year of ART initiation — 10 countries, 2004–2015
Country
CD4 
distribution
Overall Year (%)
p-value*No. Total No.
% 
(95% CI) 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Southern Africa 
Mozambique
CD4<100 66,183 282,129 23 (23–24) 39 39 34 31 29 29 28 25 21 18 18 — <0.001
CD4<200 138,453 282,129 49 (49–49) 73 71 68 65 63 62 58 53 44 38 37 — <0.001
CD4<350 233,344 282,129 83 (83–83) 93 90 91 91 90 91 90 89 85 73 71 — <0.001
Missing 164,250 446,379 37 42 33 31 30 31 32 32 30 32 39 50 — —
Namibia CD4<100 16,724 82,774 20 (20–20) 39 35 29 26 26 22 17 13 16 — — — <0.001
CD4<200 48,555 82,774 59 (58–59) 80 76 76 75 76 71 58 36 41 — — — <0.001
CD4<350 77,351 82,774 93 (93–94) 97 95 95 95 95 95 95 91 91 — — — <0.001
Missing 82,694 165,468 50 72 78 79 76 42 38 37 34 30 — — — —
Swaziland CD4<100 770 2,296 34 (31–36) 32 50 44 41 39 36 24 — — — — — 0.035
CD4<200 1,550 2,296 67 (63–71) 72 87 86 78 77 69 54 — — — — — 0.028
CD4<350 2,168 2,296 95 (93–96) 90 98 98 95 97 95 92 — — — — — 0.592
Missing 214 2,510 9 33 15 18 5 8 10 5 — — — — — —
Zambia CD4<100 310 849 36 (33–40) 23 36 37 38 33 35 — — — — — — 0.792
CD4<200 601 849 70 (67–74) 77 73 76 67 69 65 — — — — — — 0.287
CD4<350 810 849 96 (94–97) 100 93 95 96 96 95 — — — — — — 0.562
Missing 365 1,214 30 73 57 32 23 16 16 — — — — — — —
Zimbabwe CD4<100 757 1,820 42 (39–45) — — — 46 40 40 — — — — — — 0.092
CD4<200 1,424 1,820 78 (74–81) — — — 84 75% 75 — — — — — — 0.042
CD4<350 1,767 1,820 97 (95–98) — — — 97 97% 97 — — — — — — 0.756
Missing 2,076 3,896 53 — — — 55 50% 55 — — — — — — —
East Africa 
Tanzania
CD4<100 432 1,085 41 (37–44) — 40 50 40 41% 37 — — — — — — 0.581
CD4<200 804 1,085 77 (74–80) — 77 80 79 77% 77 — — — — — — 0.994
CD4<350 1039 1,085 97 (95–98) — 94 99 97 95% 99 — — — — — — 0.132
Missing 336 1,421 24 — 24 28 22 23% 22 — — — — — — —
Uganda CD4<100 438 1,166 36 (33–39) 54 50 49 30 30 28 — — — — — — <0.001†
CD4<200 859 1,166 74 (71–76) 89 85 83 78 67 60 — — — — — — <0.001†
CD4<350 1,127 1,166 96 (95–97) 99 96 99 95 99 95 — — — — — — 0.122
Missing 300 1,466 20 31 27 23 20 17 16 — — — — — — —
West Africa 
Nigeria
CD4<100 884 2,876 31 (27–34) 9 36 40 31 31 32 29 25 — — — — 0.001§
CD4<200 1,792 2,876 63 (59–67) 68 67 77 65 63 66 60 53 — — — — 0.043§
CD4<350 2,666 2,876 93 (91–94) 96 91 94 92 94 93 92 92 — — — — 0.576
Missing 620 3,496 18 33 21 20 21 18 13 16 20 — — — — —
Caribbean Haiti CD4<100 10,835 47,209 23 (23–23) 49 51 42 32 26 21 23 22 21 19 18 20 <0.001
CD4<200 20,578 47,209 44 (43–44) 75 79 77 68 55 46 46 42 39 36 32 34 <0.001
CD4<350 35,306 47,209 75 (74–75) 92 94 94 90 84 86 83 76 72 70 60 59 <0.001
Missing 25,837 60,705 43 24 36 37 33 37 30 35 31 31 32 33 53 —
Southeast Asia 
Vietnam
CD4<100 3,015 5,228 58 (55–60) — 74 63 58 59 52 — — — — — — 0.007
CD4<200 4,384 5,228 84 (81–86) — 91 87 84 86 80 — — — — — — 0.046
CD4<350 5,038 5,228 96 (95–97) — 98 97 95 97 96 — — — — — — 0.533
Missing 2,355 7,583 31 — 39 42 36 28 25 — — — — — — —
Abbreviations: ART = antiretroviral therapy; CD4 = CD4+ T-cell count (cells/µL); CI = confidence interval.
* P-value derived from logistic regression, accounting for survey design, comparing the percentage of enrollees below the specified CD4 threshold in the most recent 
calendar year with the corresponding percentage in the earliest calendar year with data available.
† Specified p-values were derived from logistic regression including calendar year of ART initiation as a continuous variable because of observed linear trend.
§ In Nigeria, the p-value compares percentages in 2006 with percentages in 2011, to best capture recent declines in prevalence of advanced disease.
128/µL to 261/µL; p<0.001), in Namibia (from 125/µL to 
230/µL; p<0.001), and in Haiti (from 103/µL to 297/µL; 
p<0.001) (Figure).
In the seven countries with less recent data, statistically 
significant declines in prevalence of advanced disease were 
observed in five countries (Table 2). Prevalence of advanced 
disease at ART initiation declined from 72% to 54% in 
Swaziland (2004–2010), from 84% to 75% in Zimbabwe 
(2007–2009), from 89% to 60% in Uganda (2004–2009), 
from 68% to 53% in Nigeria (2004–2011), and from 91% to 
80% in Vietnam (2005–2009) (Table 2) (supplemental figure; 
https://stacks.cdc.gov/view/cdc/45821). Over the same periods 
in Swaziland, Uganda, and Vietnam, statistically significant 
increases in median baseline CD4 from 143/µL to 184/µL 
(p<0.001), 89/µL to 170/µL (p<0.001), and 22/µL to 92/µL 
(p = 0.014), respectively, were observed (Figure).
Discussion
This analysis of 694,138 medical records from 10 low- and 
middle-income countries (LMIC), contributes several find-
ings relevant for ART programs in resource-limited settings. 
Observed declines in the prevalence of advanced disease at 
ART initiation in eight countries and increases in median 
baseline CD4 at ART initiation in six countries are likely 
due to increasing access to HIV testing and treatment (e.g., 
increasing numbers of facilities providing testing and treatment 
services), and increasingly inclusive ART eligibility guidelines 
(1). Despite this encouraging progress, however, a significant 
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FIGURE. Trends in median CD4+ T-cell count at antiretroviral therapy (ART) initiation — 10 countries, 2004–2015
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percentage of ART enrollees still started ART with advanced 
disease in recent years. In Haiti, which provided the most 
recent data on ART enrollees for this analysis (2015), and 
which historically has had higher than average median CD4 
at ART initiation compared with other LMIC (Table 2) (2,3), 
the percentage of ART enrollees with CD4 <200/µL was 34% 
in 2015. Similarly, in Mozambique in 2014, 37% of patients 
started ART with advanced disease. Although recent data 
from the 10 countries are limited, these data and data from 
a recent meta-analysis, which reported mean CD4 count at 
ART initiation for 27 LMIC in 2011–2013 of 186 cells/µL 
(3), suggest at least a third of ART patients in LMIC initiated 
ART with advanced disease in 2015. To reduce prevalence 
of advanced disease at ART initiation in LMIC, continued 
attention to programmatic strategies facilitating earlier HIV 
testing and linkage to care are needed, in addition to adoption 
of WHO-recommended universal ART eligibility (“treat-all”) 
guidelines for persons living with HIV (3), which stipulate that 
all patients become eligible for ART on the day of HIV diag-
nosis, regardless of CD4 count at HIV diagnosis. Early ART 
for all persons living with HIV could improve ART program 
outcomes and HIV prevention impact (4,5). For example, in 
the Strategic Timing of Antiretroviral Therapy (START) trial, 
initiating ART for patients with CD4 >500/µL rather than 
deferring ART initiation until more advanced disease stages, 
was shown to reduce risk for a composite endpoint of any 
serious acquired immunodeficiency syndrome (AIDS)–related 
event, non-AIDS–related event, or death by 57% (5). In addi-
tion, early rather than deferred ART for HIV-positive persons 
in a serodiscordant relationship was found to reduce HIV 
transmission to the HIV-negative partner by approximately 
96% (4). Among the 10 countries studied, “treat-all” guidelines 
have been adopted nationwide in nine (Haiti, Mozambique, 
Namibia, Nigeria, Swaziland, Tanzania, Uganda, Zambia, and 
Zimbabwe), whereas Vietnam is beginning to phase in “treat-
all” guidelines with nationwide adoption planned by 2020.
Given the low median baseline CD4 from Vietnam in 
2009 (92/µL), much lower than Haiti’s median baseline CD4 
the same year (219/µL), evaluation of more recent trends in 
baseline CD4 is warranted. With Vietnam’s epidemic largely 
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involving men who inject drugs, late presentation for ART 
might be partly explained by suboptimal health-seeking 
behavior in this population (6). In Vietnam and similar 
LMIC, continued monitoring of the prevalence of advanced 
HIV disease at ART initiation is necessary to inform under-
standing of ART program access, outcomes, and prevention 
strategies (because baseline CD4 gives an indication of how 
long ART enrollees have lived with an unsuppressed viral load). 
Comparing prevalence of advanced disease at ART initiation 
among demographic groups (e.g., nonpregnant females, preg-
nant females, and males) or among more affected population 
groups (e.g., sex workers and persons who inject drugs) can 
inform which populations are being reached late and therefore 
require targeted interventions (1).
Recent WHO guidelines recommend a differentiated 
approach to treatment of persons living with HIV.¶ This 
approach means that patients initiating ART with advanced 
HIV disease require additional specialized care to ensure 
optimal outcomes. For example, tuberculosis (TB) is common 
among patients starting ART with advanced HIV disease, and 
remains the most common cause of death, accounting for 
approximately 40% of deaths, half of which are undiagnosed 
before death (7). Based on recent evidence from a random-
ized trial (8), WHO recommends that the lateral flow urine 
lipoarabinomannan assay may be used to assist in the rapid 
diagnosis and treatment of disseminated TB among persons 
living with HIV admitted to hospital with CD4 <100/µL and 
symptoms of TB. WHO conditionally recommends the same 
screening approach for adult outpatients. Early identifica-
tion and treatment of disseminated TB can reduce all-cause 
mortality (8). In addition, plasma screening for cryptococ-
cal antigen (CrAg) among patients with CD4 <100/µL and 
consideration of preemptive treatment with fluconazole for 
CrAg-positive patients might reduce 12-month ART mortal-
ity (9). Co-trimoxazole prophylaxis for ART enrollees with 
CD4 <350/µL has been shown to reduce mortality (10). Use 
of these adjunctive therapies could help reduce relatively high 
12-month mortality among people taking ART in LMIC (1).
Given the importance of baseline CD4 in determining eligi-
bility for adjunctive therapies that have the potential to reduce 
mortality, it is concerning that 40% of the 694,138 medical 
records reviewed lacked documentation of the baseline CD4, 
with country-specific rates ranging from 9% in Swaziland to 
53% in Zimbabwe. Quality improvement measures to ensure 
availability of baseline CD4 data for clinical decision-making 
are warranted.
¶ World Health Organization. Guideline on when to start antiretroviral therapy 
and on preexposure prophylaxis for HIV. http://www.who.int/hiv/pub/
guidelines/earlyrelease-arv/en/.
Summary
What is already known about this topic?
Monitoring prevalence of advanced human immunodeficiency 
virus (HIV) disease (i.e., CD4+ T-cell count <200 cells/µL) among 
persons initiating antiretroviral therapy (ART) is important to 
help understand ART program outcomes, inform HIV prevention 
strategies, and forecast need for adjunctive therapies.
What is added by this report?
In an analysis of 694,138 adult ART records from 10 countries, 
the prevalence of advanced disease at ART initiation during 
2004–2015 declined in eight countries. In Mozambique 
(2004–2014), Namibia (2004–2012), and Haiti (2004–2015), 
prevalence of advanced disease at ART initiation declined from 
73% to 37% (p<0.001), 80% to 41% (p<0.001), and 75% to 34% 
(p<0.001), respectively. In the remaining seven countries with 
data available for 2004–2011, significant declines in prevalence 
of advanced disease were observed in Nigeria, Swaziland, 
Uganda, Vietnam, and Zimbabwe.
What are the implications for public health practice?
Declines in the prevalence of advanced disease at ART enroll-
ment over time in most countries are encouraging, but in 2015, 
approximately a third of new ART patients still initiated ART late. 
Adoption of World Health Organization–recommended 
“treat-all” guidelines and strategies to facilitate earlier HIV 
testing, and treatment are needed. These strategies would help 
reduce HIV-related mortality and HIV incidence.
The findings in this report are subject to at least three limi-
tations. First, cohort data varied in size and generalizability; 
statistical significance of trends in baseline CD4 over time is 
more likely with larger sample sizes and more calendar years 
of available data. Second, missing data on CD4 at ART initia-
tion might have introduced measurement error for summary 
estimates. Third, in several countries, data on more recent 
ART enrollees are needed to inform estimates of the current 
prevalence of advanced HIV disease at ART initiation.
Encouraging reductions in the prevalence of advanced disease 
at ART initiation were observed in eight of the 10 countries 
studied. This reflects the rapid scale-up of HIV testing and 
treatment services in LMIC since 2004 and evolution of HIV 
treatment guidelines encouraging earlier ART initiation. 
However, an estimated one third of new ART enrollees in 
LMIC in 2015 started ART with advanced disease, indicating 
that continued scale-up of interventions to facilitate earlier 
testing and treatment are needed. For those ART enrollees 
who do initiate ART late (3), ensuring availability of WHO-
recommended adjunctive therapies could help reduce morbid-
ity and mortality during ART.
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